ABSTRACT
Objective: To investigate the clinical effect of Xihuang Capsule combined with albumin paclitaxel in the treatment of advanced triple negative breast cancer. Methods: A total of 80 patients with advanced triple negative breast cancer admitted to Cangzhou Central Hospital were selected as the study subjects. All patients were randomly divided into the control group and the treatment group, with 40 patients in each group. Patients in the control group were given albumin paclitaxel for a cycle of 21 d, and received continuous treatment for at least three cycles. The difference between the treatment group was given six capules of Xihuang Capsules twice a day for one course of treatment for 21 d based on the treatment of control group. The clinical effects of the two groups were compared and analyzed. The KPS and VAS scores of the two groups of patients were evaluated, and the tumor markers and the incidence of adverse reactions after taking the drug were recorded for statistical analysis. Results: After treatment, the objective remission rate (ORR) was 60.0% in the control group and 75.0% in the treatment group. The disease control rate (CBR) was 77.5% in the control group and 85.7% in the treatment group. The difference between the two groups was statistically significant (P < 0.05). After treatment, KPS score and VAS score in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, CA-153 and CEA levels of tumor markers in both groups were significantly lower than those before treatment (P < 0.05), while CA-153 and CEA levels in the treatment group were lower than those in the control group (P < 0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion: Xihuang Capsule combined with albumin paclitaxel has higher clinical efficacy and safety in patients with advanced triple negative breast cancer.
ABSTRACT
Objective:To explore the curative effect and toxic and side effects of Xihuang Capsule in the patients with advanced esophageal cancer treated with chemoradiotherapy, and to clarify its mechanism.Methods:The patients with advanced esophagealcancer without treatment were selected.The patients treated with Xihuang Capsule combined with concurrent chemoradiotherapy were defined as combination treatment group(n=27), and then other 27 patients were randomly selected from 87 patients treated with concurrent chemoradiotherapy alone as chemoradiotherapy group.The observation time was 90 d from the begining of chemotherapy.The differences in KPS, degree of dysphagia, incidence, occurrence time and degrees of acute radiation esophagitis of the patients in two groups were compared, and local control of tumor was analyzed.Results: After treatment, the KPS scores of the pateints in two groups were decreased, and the KPS score in combined treatment group was significantly higher than that in chemoradiotherapy group (P0.05).Conclusion:Xihuang Capsule can improve the quality of life, reduce dysphagia degree and the incidence of acute radiation esophagitis,and delay the occurrence time;it can be used as an effective auxiliary treatment of advanced esophageal cancer.
ABSTRACT
Objective:To study the effect of Xihuang Capsule combined with GP regimen on the serum levels of tumor necrosis factor-oα (TNF-α),vascular endothelial growth factor (VEGF),matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) of patients with advanced breast cancer.Methods:88 patients with advanced breast cancer admitted in our hospital from March 2014 to February 2015 were selected and divided into the observation group and the control group according to the order of admission.The control group was treated by the GP program,the observation group was given Xihuang capsule combined with GP regimen.The serum levels of TNF-α,VEGF,MMP-2 and MMP-9 in the two groups were compared before and after treatment.The clinical efficacy and incidence of side effects were analyzed.Results:The total effective rate of observation group was significantly higher than that of the control group [84.09％ (37/44) vs 50.00％ (22/44)] (P＜0.05).There was no significant difference in the serum levels of TNF-α,VEGF,MMP-2 and MMP-9 between the two groups before treatment (P＞0.05).After treatment,the serum TNF-α,VEGF,MMP-2 and MMP-9 levels were significantly lower than those before treatment (P＜0.05).The serum levels of TNF-α,VEGF,MMP-2 and MMP-9 of observation group were significantly lower than those of the control group (P＜0.05).There was no significant difference in the incidence rate of nausea and vomiting between the two groups (P＞0.05).The incidence ofalopecia,diarrhea,abnormal liver function,decreased appetite,anemia and leukopenia in the observation group were significantly lower than those of the control group (P＜0.05).Conclusion:Xihuang Capsule combined with GP regimen could more effectively reduce the levels of serum TNF-α,VEGF,MMP-2 and MMP-9 of patients with advanced breast cancer than GP regime alone with higher safety.